CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.

American Journal of Cardiovascular Drugs, published by ADIS INT LTD, is a premier peer-reviewed journal dedicated to the field of cardiology and cardiovascular medicine. With an ISSN of 1175-3277 and an E-ISSN of 1179-187X, this esteemed journal has established itself as a crucial platform for disseminating high-quality research since its inception in 2001. It holds a significant position in its domain, ranking in the second quartile (Q2) across several categories including Cardiology, Medicine (miscellaneous), and Pharmacology (medical) for the year 2023. With its Scopus ranks placing it in the 81st percentile for Cardiology and 77th percentile for Pharmacology, the journal is highly regarded among professionals, researchers, and students alike. While it is not an open-access journal, its comprehensive articles and systematic reviews provide an in-depth exploration of cardiovascular drug therapy, therapeutic advancements, and clinical practices, making it an invaluable resource for anyone invested in the future of cardiovascular health.

Current Vascular Pharmacology is a premier academic journal published by Bentham Science Publications Ltd, focusing on the intersection of pharmacology and cardiovascular medicine. With an impact factor that reflects its significance in the field, this journal ranks in the Q1 category for both Pharmacology and Cardiology, showcasing its dedication to high-quality research. Its Scopus ranks place it in the top percentile of its categories, highlighting its influence among scholars and practitioners alike. Issued since 2003 and continuing through 2024, Current Vascular Pharmacology aims to disseminate cutting-edge findings and foster knowledge exchange among researchers, professionals, and students engaged in cardiovascular pharmacology. Despite being a subscription-based journal, it remains a vital resource for those seeking the latest advancements in drug development and therapeutic interventions for vascular diseases. Located in the United Arab Emirates, the journal serves as an essential platform for global discourse on vascular health.

CIRCULATION is a premier journal in the field of cardiology and cardiovascular medicine, published by Lippincott Williams & Wilkins. With a distinguished history dating back to 1950, the journal has consistently been at the forefront of critical research, showcasing significant advancements and discoveries in cardiovascular health. It holds a remarkable Q1 ranking in both the fields of Cardiology and Physiology (medical) according to the 2023 category quartiles, demonstrating its influential role among the top publications in these disciplines. With an impressive Scopus ranking, placed 3rd out of 387 in Cardiology and 2nd out of 113 in Physiology, CIRCULATION is essential reading for researchers, practitioners, and students passionate about advancing their understanding of heart health and related medical sciences. Although the journal is not open access, it continues to foster scholarly exchange and innovation in cardiovascular research, making it an indispensable resource for quality insights and groundbreaking studies.

PROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

Acta Cardiologica Sinica is a distinguished journal dedicated to the advancement of cardiology and cardiovascular medicine, published by the Taiwan Society of Cardiology. Since its inception in 1988, this journal has provided a platform for researchers and clinicians to share cutting-edge findings and insights into cardiac health, cardiovascular diseases, and innovative treatment strategies. With an impressive Q3 classification in the Cardiology category for 2023, the journal is recognized for its contributions to the field, ranked #208 out of 387 in Scopus, placing it within the 46th percentile of medical journals. Although it currently does not offer open access options, it remains a valued resource for the global cardiovascular community. The journal's commitment to disseminating high-quality research papers, reviews, and case studies ensures that it plays a vital role in improving cardiovascular health practices and outcomes. For researchers, professionals, and students alike, Acta Cardiologica Sinica is essential reading for staying informed about the latest developments in cardiology.

Cardiology Journal, published by VIA MEDICA, stands as a prominent resource in the field of cardiology and cardiovascular medicine, with an ISSN of 1897-5593 and an E-ISSN of 1898-018X. Recognized for its Open Access model established since 1994, this journal facilitates widespread dissemination of critical research findings, allowing practitioners and researchers globally to access valuable insights without barriers. Based in Poland, with an address at UL SWIETOKRZYSKA 73, 80-180 GDANSK, it has achieved a respectable Q2 classification in 2023 for both Cardiology and Miscellaneous Medicine categories, reflecting its influence and quality within the scholarly community. With a Scopus ranking placing it at #117 out of 387 in Cardiology, it lies within the 69th percentile, underpinning its commitment to advancing knowledge in cardiovascular health. The journal’s converged years extending from 2006 to 2024 ensure it captures ongoing developments in a rapidly evolving field. As such, the Cardiology Journal serves as an indispensable platform for researchers, professionals, and students dedicated to exploring the frontiers of cardiac science and improving patient care.

The European Journal of Preventive Cardiology, published by Oxford University Press, is a leading international journal dedicated to the field of cardiology and cardiovascular medicine. With an impact factor that underscores its prestige—ranking in the top quartile (Q1) of both cardiology and epidemiology categories—the journal serves as a critical resource for researchers and practitioners seeking to advance their understanding of preventive strategies in cardiovascular health. Since its inception in 1999, it has provided a platform for high-quality research and reviews that address the epidemiology of cardiovascular diseases, risk factor management, and innovative prevention methodologies. Notably, it currently ranks #21 out of 387 in Medicine - Cardiology and #13 out of 148 in Medicine - Epidemiology according to Scopus, highlighting its influential position in these essential biomedical fields. The journal also provides open access options, allowing both readers and authors the opportunity to engage with groundbreaking research and enhance the dissemination of knowledge. With a commitment to excellence, the European Journal of Preventive Cardiology is an invaluable asset for those dedicated to the prevention of cardiovascular diseases.

Cardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.